Vivere meglio
la sessualità

Home page
Archivio news
Per fortuna non
siamo tutti uguali
Fare sesso e
fare all'amore

1 - 2 - 3

I luoghi comuni:
La scelta del partner (1)

quanti partner (2)
quanti partner (3)
Quanti orgasmi (4)
To have sex or
make love
Voglia di conoscersi,
Il bacio
La passione
I Porno vorrebbero
farci credere che...
Il corpo e la
Il corpo
Il desiderio
La seduzione
La gelosia
Il tradimento
Il contatto corporeo
Il piacere
Cosa si può fare
Cosa piace a lei
cosa piace a lui
La trasgressione:
farlo in tre
o più

A cura della Dott.ssa
Giuliana Proietti

La timidezza

La fedeltà

Chi è il Dott.
Antonio Turetta

Chi è la Dott.ssa
Serenella Salomoni

Chi è il Prof. Dott.
Lamberto Coppola




By Marco Dal Negro


Italiano - English 


Questions about HPV and HPV vaccine (2013-02-20)


What is causing a surge in HPV infections associated with head and neck cancers in white men?
 Will an HPV vaccine received at age 11 last long enough to protect women in their 40s when cervical cancer tends to strike?
In the fight against HPV, Emory gynecologist Kevin Ault is taking the long view.

Most cervical cancers are caused by two varieties of HPV (human papillomavirus), and a vaccine approved in 2006 can protect against both of them. Still, the long-term effectiveness of the vaccine is unknown.

"Let's say a girl in her early teens, someone like my daughter, gets the vaccine," Ault says. "But the average age of diagnosis for cervical cancer in the United States is the early 40s. The vaccine's shield has to last for decades for it to actually protect her against disease."

HPV itself is a wily adversary. Most people who become infected with HPV do not know that they have it. At least 80% of sexually active men and women carry the virus at some point in their lives, but in most cases, the immune system clears the virus from the body.
Researchers have found that the virus hides in "crypts" in the cervix, anus, tonsils, base of tongue, and throat. More than 40 types of HPV can infect both men and women. Two types, HPV-16 and HPV-18, have been shown to cause cervical cancer, as well as most anal cancers and some vaginal, vulvar, penile, and head and neck cancers.

Ault is leading an NIH-funded study at Emory that looks at how long vaccine recipients maintain "immune memory." That is, how long does the immune system stay ready to fight the virus after receiving the vaccine? Study participants are healthy women between the ages of 18 and 26, who will be followed for three years. The research takes into account women who have received two rather than the recommended three doses of the HPV vaccine.

Ault says recent findings about the pertussis vaccine may shed light on the long-term effectiveness of the HPV vaccine. In the 1990s, children in the United States began receiving a newer version of the pertussis vaccine that had fewer side effects than the original version. Researchers at Kaiser Permanente recently showed that immune protection fades faster with the newer vaccine, waning substantially five years after the last shot. They suggest that this lack of protection may be a contributing factor in the largest reported outbreak of pertussis in 50 years, which occurred in 2012.

"We wouldn't want people to rely on something that lasts a relatively short time," Ault says. His study will give clues on whether patients will need periodic HPV booster shots, like those for tetanus.

Evidence is emerging that HPV infection also is contributing to head and neck cancer. In a 2011 article published in Oncology, researchers at Emory's Winship Cancer Institute reported a "surge" in the past two decades of HPV-related tumors in the tongue and tonsils, especially among white men. Part of the increase is due to more sophisticated and intentional ways of looking for HPV, says Emory oncologist Jonathan Beitler.

"Ten years ago, it was not a perceived problem, but our world has changed," he says. "This used to be a disease of older men, smokers, and drinkers. Now we are seeing patients who are younger and more educated, without those traditional risk factors."

Beitler estimates that three-quarters of the patients he sees with head and neck cancer have HPV-related tumors. The surge may be connected to increased practices of oral sex and/or marijuana consumption. For example, having six or more oral sex partners increases a person's risk of developing head and neck cancer nine-fold, amounting to more than the increased risk coming from smoking.

On a brighter side, patients who have HPV-related tumors generally have better outcomes than those whose tumors have a different origin. The survival rates of these patients are higher, with five-year survival rates of 75% to 80%, compared with 50% for HPV-negative tumors.

The higher survival rates and younger patient profiles mean that oncologists treating head and neck cancer are trying approaches such as minimally invasive surgery and drugs that may have fewer side effects. "Our current challenge is figuring out how to de-intensify therapy in the best way and still cure the patient," Beitler says. "We want to make it possible for patients to get back to their lives."

In a national clinical trial in which Beitler is involved, researchers are comparing two anticancer drugs to treat head and neck cancer in combination with radiation.
One approach uses a standard DNA-damaging agent, cisplatin, with the test drug, cetuximab, to block a growth factor found on head and neck cancer cells. The aim is to determine whether cetuximab can provide the same level of efficacy with reduced side effects, such as mouth sores.
The investigators also hope to learn about the genes of the HPV varieties that contribute to activity in head and neck cancer.

Beitler notes that HPV varieties may continue to shift, indicating that vaccine studies like Ault's could guide updates in vaccine practices for both men and women.


For more information
Emory University



Home di - Salute - Sessualità - Gola - Depressione - I consigli del nonno - Musica - Grafologia - Ambiente - Per saperne di più - Viaggi: tutto in una pagina - Meteo - Ridere - Mix

Cerca nel sito

Chi siamo e come contattarci

Copyright © 1998/2018 tutti i diritti sono riservati eccetto quelli già di altri proprietari.